Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Survival Without Progression × Methotrexate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 246 Leukemia 185 Lymphoma 137 Leukemia, Myeloid, Acute 103 Burkitt Lymphoma 90 Myelodysplastic Syndromes 79 Lymphoma, Non-Hodgkin 65 Lymphoma, Large B-Cell, Diffuse 59 Breast Neoplasms 59 Leukemia, Lymphocytic, Chronic, B-Cell 49 Lymphoma, Mantle-Cell 47 Hodgkin Disease 47 Graft vs Host Disease 46 Lymphoma, Follicular 45 Leukemia, Myeloid, Accelerated Phase 45 Multiple Myeloma 39 Leukemia, Myeloid, Chronic-Phase 39 Congenital Abnormalities 39 Myeloproliferative Disorders 38 Blast Crisis 38 Leukemia, Myelomonocytic, Chronic 37 Leukemia, Biphenotypic, Acute 35 Recurrence 34 Lymphoma, Large-Cell, Immunoblastic 33 Lymphoma, B-Cell, Marginal Zone 31 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 30 Primary Myelofibrosis 27 Osteosarcoma 26 Neoplasms, Plasma Cell 25 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡